Results
malaria, diarrhoea, fever
MALARIA, DISEASE
Using a Bayesian GLMM statistical model, we analysed how childhood disease incidence changed through the baseline, mid-line, and end-line longitudinal panel data. We found that compared to the control group, the incidence of the outcomes of interest among children under 5 in the intervention group changed to a 95% credible interval of 0.661–1.128 (median: 0.862) for diarrhoea and a 95% credible interval of 0.670–1.107 (median: 0.860) for high fever. In addition, the incidence of diarrhoea in the intervention group was lower than that of the control group, with a probability of 86.7%, and the incidence of malaria was lower than that of the control group, with a probability of 88.6%. The total cost over the 10 years of period was estimated to $1,714,676, including start-up costs of $21,433 (1.3%), capital costs of $251,796 (14.7%) and recurrent costs of $1,441,448 (84%).Based on the statistical and economic models above, a cost-effectiveness analysis was performed by constructing 32,000 probability samples. In Cost-effectiveness plane.We measured the probability of averting 1 DALY at a cost less than Ghana’s GDP per capita and accepting five different cost-effectiveness thresholds. In Cost-effectiveness acceptability curve.Next, a cost-benefit analysis was conducted by converting health and non-health effects into benefits of monetary value. Overall, the mean and median of the cost-benefit ratio were 6.4 and 4.8, respectively. Of the 32,000 probability samples, 85.7% had a cost-benefit ratio of more than 1, and 65.8% had a cost-benefit ratio of more than 3. The median current value of the net benefit was $6.5 million. In Violin plots on cost-benefit ratio.Violin plots on net present value of benefit.